UPDATE 1-US senators push drugmakers for details on low-cost insulin programs

Two U.S. senators are demanding that the nation's three largest insulin makers, Novo Nordisk , Eli Lilly, and Sanofi, provide details by Sept. 15 of their programs to help Americans get their insulin for $35 a month or less. Democratic Senators Maggie Hassan and Tina Smith sent a letter asking the drugmakers for information on eligibility criteria for the programs, including whether a patient’s insurance status or income barred them from joining, and the steps insulin users had to take to sign up. Novo, Lilly and Sanofi, which account for 90% of the U.S. insulin market, pledged in March to lower the list prices of many of their insulin products by 70%-78% later this year or in 2024.